Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.80.

A number of research analysts recently issued reports on CMPX shares. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after acquiring an additional 356,352 shares during the period. Barclays PLC lifted its stake in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics during the third quarter worth approximately $79,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Compass Therapeutics in the second quarter valued at approximately $41,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $2.61 on Friday. The firm has a market cap of $359.11 million, a P/E ratio of -7.05 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $2.73. The firm’s 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.53.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, sell-side analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.